Please login to create your UC TechAlerts.
Request a new password for
Required
Novel compositions and methods for targeted replacement of endogenous T-cell receptor with a chimeric antigen receptor
Brief description not available
Gene Targets For Gamma-Delta T Cell Cytotoxicity Against Tumor Cells
Gene Targets For Manipulating T Cell Behavior
METHOD FOR MANUFACTURING THERAPEUTIC IMMUNE CELLS
Chimeric antigen receptor (CAR) T cells have so far shown limited efficacy on brain and solid tumors. UCSF investigators have developed a method of manufacturing recombinant immune cells by pre-treating them with a combination of small molecules to increase the number of CAR T cells in the tumor microenvironment and improve the survival of animal models bearing glioma in the brain relative to CAR T cells that have not received the pre-treatment. These results may be applicable to other solid tumors.
LONG NON-CODING RNAS (LNCRNAS) AS THERAPEUTIC TARGETS IN GLIOMA
A Diagnostic And Extent Of Disease Multigene Assay For Thyroid Neoplasms
Monocytes Associated With Immunotherapy Resistance
Distinct Metabolic States Guide Maturation of Inflammatory and Tolerogenic Dendritic Cells
Scientists at UCSF and the Parker Institute of Cancer Immunotherapy have developed methods for characterizing dendritic cells as well as methods for identifying a dendritic cell as either an inflammatory or a tolerogenic dendritic cell. Their results provide important insights into previously obscured metabolic heterogeneity impacting immune profiles of immunogenic and tolerogenic dendritic cells (DC).
Humanized Anti-Integrin aVß8 mAb to Inhibit TGFß Activity and Enhance Anti-Tumor Immunity for Immunotherapy
Improving primary human NK cell expansion with a chimeric cytokine receptor
Natural Killer (NK) cells are innate lymphocytes with the ability to lyse tumor cells. One limitation of NK cells when encountering tumor cells is that they can’t control their own proliferation and expansion to increase their numbers at the tumor site. Current approaches to increase NK cell numbers and stimulate NK-cell anti-cancer functions include systemic administration of recombinant cytokines (IL-15, IL-2, or IL-12) that exhibit systemic or local toxicity or constitutive expression of IL-15 in transduced NK cells. Researchers at UCSF have engineered NK cells with a chimeric cytokine receptor (CCR) that provides autocrine signaling through the secretion of IFNγ, which subsequently enhances NK cell proliferation and function to support NK cell anti-cancer immune response specifically at the tumor site while avoiding recombinant cytokine- related toxicity.
Methods for Culturing Glioblastoma Cancer Cells and for Inhibiting Invasion of Cancer
An Extracellular Vesicle Based Liquid Biopsy for Treatment Monitoring and Early Detection of Tumor Recurrence in Glioblastoma Patients
Single-Cell Analysis of Somatic Mutation Burden
Integrin Activation to Bypass the CD47 Macrophage Checkpoint and Enable Phagocytosis of Cancer Cells
ELONGATION FACTOR 1-ALPHA INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA / MYC-DRIVEN CANCERS
Coordinately-Regulated Retroviral Gene Delivery System
Blood Based T Cell Biomarker For Cancer Diagnosis And Treatment
In cancer care, specific characteristics of T cells can be used to measure a patient’s response to immunotherapy. Using single-cell RNA-sequencing coupled with TCR sequencing, scientists at UCSF and Harvard detected CD8+ T cell clones shared between blood and tumor in mice and melanoma patients, characterized these matching clones in blood and tumor, and identified potential biomarkers for their isolation in the blood. Their method reveals specific protein signatures (biomarkers) on the surface of T cells that can be therapeutically targeted to treat melanoma and other forms of cancer. It presents a very attractive alternative to obtaining invasive biopsy samples from the tumor, and can be done much more quickly.
T cell Receptor cDNAs to Treat Gliomas
T Cell Receptor cDNAs to Treat Gliomas
Gene Expression Signatures of Intratumoral T cells as Biomarkers of Clinical Response and Increased Survival with Immune Checkpoint Inhibitor Therapy in Bladder Cancer
Non-Invasive Lesion-Specific Classification Of Nevus And Melanoma Using A MicroRNA Signature.
Neoantigen-specific antibodies for chemically directed immune targeting of KRAS tumors
UCSF scientists have discovered novel antibodies that can specifically and selectively recognize tumor-derived neoantigens. The antibodies can be used for IgG, BiTE or CAR-T-based targeted immunotherapy and small molecule-based directed immune targeting via combination therapy. This dual therapeutic approach has the potential to specifically recognize and treat KRAS (G12C) cancer cell populations with high specificity, significantly improve cancer treatment outcomes, and overcome risk of treatment resistance in patients.
Chimeric Kinase Inhibitors with Increased Activity
This invention describes newly generated kinase inhibitors that demonstrate enhanced and attenuated action over their parent kinase inhibitors. These molecules can be used alone but, when combined with novel blocking molecules, the action of these chimeric kinases can be targeted for action in the central nervous system (CNS).
NOVEL ANTIBODIES AGAINST EPHA2 FOR RESEARCH, DIAGNOSIS, AND TREATMENT OF CANCER
A novel monoclonal human antibody specific to the cell-surface exposed protein EphA2, which is over-expressed in many forms of cancer and is a validated therapeutic target.
4D-seq: Single Cell RNA-sequencing with in situ Spatiotemporal Information
To develop a novel imaging-based single cell RNA-sequencing (scRNA-Seq) platform that allows capturing of spatiotemporal information and cellular behavior of the sequenced cells within tissue.